title: Antiendotoxin therapies for septic shock.
abstract: Gram-negative shock is thought to result primarily from the effects of endotoxin, a component of the bacterial outer membrane. Accordingly, therapies aimed at inhibiting, neutralizing, or clearing endotoxin have been extensively explored. Despite over 30 years of research, no antiendotoxin approach to the treatment of human septic shock is of proven benefit. In recent randomized clinical trials of monoclonal antibodies against endotoxin, therapeutic efficacy was not convincingly demonstrated. This result, however, does not eliminate the possibility that other antiendotoxin therapies may be effective. The antibodies used in these clinical trials do not appear to neutralize endotoxin in vitro and are not reproducibly protective in animal models of sepsis. Newer agents with well-defined mechanisms of antiendotoxin activity may help clarify the role of endotoxin in septic shock and prove useful therapy for some patients.
authors.affiliation: Critical Care Department, Children's National Medical Center, Washington, D.C.
authors.forename: C C
authors.initials: CC
authors.lastname: Corriveau
authors.forename: R L
authors.initials: RL
authors.lastname: Danner
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D004731:Endotoxins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008050:Lipid A / Q000031:analogs & derivatives / Q000494:pharmacology; D011112:Polymyxin B / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D012772:Shock, Septic / Q000628:therapy*
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D004731:Endotoxins; D008050:Lipid A; D011112:Polymyxin B